Opnurasib

Opnurasib
Identifiers
	IUPAC name 1-[6-[4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one;
CAS Number	2653994-08-0;
PubChem CID	156501355;
ChemSpider	115007151;
UNII	Q3W0H3V1LQ;
ChEMBL	ChEMBL5077861;
Chemical and physical data
Formula	C29H28ClN7O
Molar mass	526.04 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC1=CC2=C(C=NN2)C(=C1Cl)C3=C(N(N=C3C4=CC5=C(C=C4)N(N=C5)C)C6CC7(C6)CN(C7)C(=O)C=C)C;
	InChI InChI=1S/C29H28ClN7O/c1-5-24(38)36-14-29(15-36)10-20(11-29)37-17(3)25(26-21-13-31-33-22(21)8-16(2)27(26)30)28(34-37)18-6-7-23-19(9-18)12-32-35(23)4/h5-9,12-13,20H,1,10-11,14-15H2,2-4H3,(H,31,33); Key:AZUYLZMQTIKGSC-UHFFFAOYSA-N;

Opnurasib (JDQ-443) is a small-molecule covalent KRASG12C inhibitor developed for non-small-cell lung cancer.^[1]^[2]^[3]^[4]

References

^ Weiss, Andreas; Lorthiois, Edwige; Barys, Louise; Beyer, Kim S.; Bomio-Confaglia, Claudio; Burks, Heather; Chen, Xueying; Cui, Xiaoming; de Kanter, Ruben; Dharmarajan, Lekshmi; Fedele, Carmine; Gerspacher, Marc; Guthy, Daniel Alexander; Head, Victoria; Jaeger, Ashley; Núñez, Eloísa Jiménez; Kearns, Jeffrey D.; Leblanc, Catherine; Maira, Sauveur-Michel; Murphy, Jason; Oakman, Helen; Ostermann, Nils; Ottl, Johannes; Rigollier, Pascal; Roman, Danielle; Schnell, Christian; Sedrani, Richard; Shimizu, Toshio; Stringer, Rowan; Vaupel, Andrea; Voshol, Hans; Wessels, Peter; Widmer, Toni; Wilcken, Rainer; Xu, Kun; Zecri, Frederic; Farago, Anna F.; Cotesta, Simona; Brachmann, Saskia M. (2 June 2022). "Discovery, Preclinical Characterization, and Early Clinical Activity of JDQ443, a Structurally Novel, Potent, and Selective Covalent Oral Inhibitor of KRASG12C". Cancer Discovery. 12 (6): 1500–1517. doi:10.1158/2159-8290.CD-22-0158. PMC 9394399. PMID 35404998.
^ Lorthiois, Edwige; Gerspacher, Marc; Beyer, Kim S.; Vaupel, Andrea; Leblanc, Catherine; Stringer, Rowan; Weiss, Andreas; Wilcken, Rainer; Guthy, Daniel A.; Lingel, Andreas; Bomio-Confaglia, Claudio; Machauer, Rainer; Rigollier, Pascal; Ottl, Johannes; Arz, Dorothee; Bernet, Pascal; Desjonqueres, Gaëlle; Dussauge, Solene; Kazic-Legueux, Malika; Lozac’h, Marie-Anne; Mura, Christophe; Sorge, Mickaël; Todorov, Milen; Warin, Nicolas; Zink, Florence; Voshol, Hans; Zecri, Frederic J.; Sedrani, Richard C.; Ostermann, Nils; Brachmann, Saskia M.; Cotesta, Simona (22 December 2022). "JDQ443, a Structurally Novel, Pyrazole-Based, Covalent Inhibitor of KRAS G12C for the Treatment of Solid Tumors". Journal of Medicinal Chemistry. 65 (24): 16173–16203. doi:10.1021/acs.jmedchem.2c01438. PMID 36399068. S2CID 253626954.
^ Lindsay, Colin R; Veluswamy, Rajwanth; Castro, Gilberto; Tan, Daniel Shao-Weng; Caparica, Rafael; Glaser, Sabine; Malhotra, Shweta; Boran, Aislyn; Felip, Enriqueta (1 June 2023). "A phase II trial of JDQ443 in KRAS G12C -mutated NSCLC with PD-L1 expression". Journal of Clinical Oncology. 41 (16_suppl): TPS9158. doi:10.1200/JCO.2023.41.16_suppl.TPS9158. S2CID 258169371.
^ Cassier, Philippe Alexandre; Dooms, Christophe Alfons; Gazzah, Anas; Felip, Enriqueta; Steeghs, Neeltje; Rohrberg, Kristoffer Staal; De Braud, Filippo G.; Solomon, Benjamin J.; Schuler, Martin H.; Tan, Daniel Shao-Weng; Yamamoto, Noboru; Loong, Herbert H. F.; Cho, Byoung Chul; Wolf, Juergen; Lin, Chia-Chi; Negrao, Marcelo Vailati; Werner, Lillian; Cui, Xiaoming; Farago, Anna F.; de Miguel, Maria J. (1 June 2023). "KontRASt-01 update: Safety and efficacy of JDQ443 in KRAS G12C -mutated solid tumors including non-small cell lung cancer (NSCLC)". Journal of Clinical Oncology. 41 (16_suppl): 9007. doi:10.1200/JCO.2023.41.16_suppl.9007. S2CID 259079866.

This pharmacology-related article is a stub. You can help Wikipedia by expanding it.

[1] Weiss, Andreas; Lorthiois, Edwige; Barys, Louise; Beyer, Kim S.; Bomio-Confaglia, Claudio; Burks, Heather; Chen, Xueying; Cui, Xiaoming; de Kanter, Ruben; Dharmarajan, Lekshmi; Fedele, Carmine; Gerspacher, Marc; Guthy, Daniel Alexander; Head, Victoria; Jaeger, Ashley; Núñez, Eloísa Jiménez; Kearns, Jeffrey D.; Leblanc, Catherine; Maira, Sauveur-Michel; Murphy, Jason; Oakman, Helen; Ostermann, Nils; Ottl, Johannes; Rigollier, Pascal; Roman, Danielle; Schnell, Christian; Sedrani, Richard; Shimizu, Toshio; Stringer, Rowan; Vaupel, Andrea; Voshol, Hans; Wessels, Peter; Widmer, Toni; Wilcken, Rainer; Xu, Kun; Zecri, Frederic; Farago, Anna F.; Cotesta, Simona; Brachmann, Saskia M. (2 June 2022). "Discovery, Preclinical Characterization, and Early Clinical Activity of JDQ443, a Structurally Novel, Potent, and Selective Covalent Oral Inhibitor of KRASG12C". Cancer Discovery. 12 (6): 1500–1517. doi:10.1158/2159-8290.CD-22-0158. PMC 9394399. PMID 35404998.

[2] Lorthiois, Edwige; Gerspacher, Marc; Beyer, Kim S.; Vaupel, Andrea; Leblanc, Catherine; Stringer, Rowan; Weiss, Andreas; Wilcken, Rainer; Guthy, Daniel A.; Lingel, Andreas; Bomio-Confaglia, Claudio; Machauer, Rainer; Rigollier, Pascal; Ottl, Johannes; Arz, Dorothee; Bernet, Pascal; Desjonqueres, Gaëlle; Dussauge, Solene; Kazic-Legueux, Malika; Lozac’h, Marie-Anne; Mura, Christophe; Sorge, Mickaël; Todorov, Milen; Warin, Nicolas; Zink, Florence; Voshol, Hans; Zecri, Frederic J.; Sedrani, Richard C.; Ostermann, Nils; Brachmann, Saskia M.; Cotesta, Simona (22 December 2022). "JDQ443, a Structurally Novel, Pyrazole-Based, Covalent Inhibitor of KRAS G12C for the Treatment of Solid Tumors". Journal of Medicinal Chemistry. 65 (24): 16173–16203. doi:10.1021/acs.jmedchem.2c01438. PMID 36399068. S2CID 253626954.

[3] Lindsay, Colin R; Veluswamy, Rajwanth; Castro, Gilberto; Tan, Daniel Shao-Weng; Caparica, Rafael; Glaser, Sabine; Malhotra, Shweta; Boran, Aislyn; Felip, Enriqueta (1 June 2023). "A phase II trial of JDQ443 in KRAS G12C -mutated NSCLC with PD-L1 expression". Journal of Clinical Oncology. 41 (16_suppl): TPS9158. doi:10.1200/JCO.2023.41.16_suppl.TPS9158. S2CID 258169371.

[4] Cassier, Philippe Alexandre; Dooms, Christophe Alfons; Gazzah, Anas; Felip, Enriqueta; Steeghs, Neeltje; Rohrberg, Kristoffer Staal; De Braud, Filippo G.; Solomon, Benjamin J.; Schuler, Martin H.; Tan, Daniel Shao-Weng; Yamamoto, Noboru; Loong, Herbert H. F.; Cho, Byoung Chul; Wolf, Juergen; Lin, Chia-Chi; Negrao, Marcelo Vailati; Werner, Lillian; Cui, Xiaoming; Farago, Anna F.; de Miguel, Maria J. (1 June 2023). "KontRASt-01 update: Safety and efficacy of JDQ443 in KRAS G12C -mutated solid tumors including non-small cell lung cancer (NSCLC)". Journal of Clinical Oncology. 41 (16_suppl): 9007. doi:10.1200/JCO.2023.41.16_suppl.9007. S2CID 259079866.

[1]

[2]

[3]

[4]

Identifiers

IUPAC name 1-[6-[4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one
CAS Number	2653994-08-0
PubChem CID	156501355
ChemSpider	115007151
UNII	Q3W0H3V1LQ
ChEMBL	ChEMBL5077861
Chemical and physical data
Formula	C₂₉H₂₈ClN₇O
Molar mass	526.04 g·mol⁻¹
3D model (JSmol)	Interactive image
SMILES CC1=CC2=C(C=NN2)C(=C1Cl)C3=C(N(N=C3C4=CC5=C(C=C4)N(N=C5)C)C6CC7(C6)CN(C7)C(=O)C=C)C
InChI InChI=1S/C29H28ClN7O/c1-5-24(38)36-14-29(15-36)10-20(11-29)37-17(3)25(26-21-13-31-33-22(21)8-16(2)27(26)30)28(34-37)18-6-7-23-19(9-18)12-32-35(23)4/h5-9,12-13,20H,1,10-11,14-15H2,2-4H3,(H,31,33) Key:AZUYLZMQTIKGSC-UHFFFAOYSA-N